Adopting an orphan
- PMID: 15940282
- PMCID: PMC1369105
- DOI: 10.1038/sj.embor.7400450
Adopting an orphan
Abstract
Incentives to develop drugs for rare disorders raise hopes and controversy
Comment in
-
Confusion over Article 8.EMBO Rep. 2005 Aug;6(8):690. doi: 10.1038/sj.embor.7400485. EMBO Rep. 2005. PMID: 16065056 Free PMC article. No abstract available.
References
-
- Alcimed (2004) Study on the price of orphan drugs. 16 Nov. Paris, France: Alcimed. http://pharmacos.eudra.org/F2/orphanmp/index.htm
-
- Bosanquet N, Domenighetti G, Beresniak A, Auray J-P, Crivelli L, Richard L, Howard P (2003) Equity, access and economic evaluation in rare diseases: the impact of orphan drug legislation on health policy and patient care. Pharm Dev Regul 1: 151–157
-
- EBE/EuropaBio (2005) White paper: towards an optimal orphan medicinal products (OMP) framework in Europe. Brussels, Belgium: EBE (www.ebe-efpia.org), EuropaBio (www.europabio.org)
-
- Haffner ME, Whitley J, Moses M (2002) Two decades of orphan product development. Nat Rev Drug Discov 1: 821–825 - PubMed
-
- Maeder T (2003) The orphan drug backlash. Sci Am 288: 80–87 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
